Altimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH

Sep 1, 2020

Company anticipates first-in-human trials to start in Q4 2020